Literature DB >> 16042225

The mechanism of action of methylprednisolone in the treatment of multiple sclerosis.

J S Sloka1, M Stefanelli.   

Abstract

Methylprednisolone plays an important role in the current treatment of multiple sclerosis (MS), particularly in the acute phase of relapse. It acts in various ways to decrease the inflammatory cycle including: dampening the inflammatory cytokine cascade, inhibiting the activation of T cells, decreasing the extravasation of immune cells into the central nervous system, facilitating the apoptosis of activated immune cells, and indirectly decreasing the cytotoxic effects of nitric oxide and tumor necrosis factor alpha. This paper reviews the most recent observations on these mechanisms both to understand the disease mechanism and its treatment. As more becomes known about these mechanisms, it may become possible to design treatment regimes that are more specific towards both the individual and the disease state.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16042225     DOI: 10.1191/1352458505ms1190oa

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  42 in total

Review 1.  Rehabilitation interventions in multiple sclerosis: an overview.

Authors:  Serafin Beer; Fary Khan; Jürg Kesselring
Journal:  J Neurol       Date:  2012-07-08       Impact factor: 4.849

Review 2.  Molecular and cellular immune mediators of neuroprotection.

Authors:  Nicolas P Turrin; Serge Rivest
Journal:  Mol Neurobiol       Date:  2006-12       Impact factor: 5.590

3.  Cerebrovascular hemodynamic changes in multiple sclerosis patients during head-up tilt table test: effect of high-dose intravenous steroid treatment.

Authors:  Zsolt Mezei; Laszlo Olah; Laszlo Kardos; Reka Katalin Kovacs; Laszlo Csiba; Tunde Csepany
Journal:  J Neurol       Date:  2013-06-12       Impact factor: 4.849

Review 4.  Drug therapy for multiple sclerosis.

Authors:  Eleonora Tavazzi; Marco Rovaris; Loredana La Mantia
Journal:  CMAJ       Date:  2014-04-22       Impact factor: 8.262

Review 5.  [Multiple sclerosis : rehabilitation and long-term course].

Authors:  S Beer; J Kesselring
Journal:  Ophthalmologe       Date:  2014-08       Impact factor: 1.059

6.  Microglia polarization by methylprednizolone acetate accelerates cuprizone induced demyelination.

Authors:  Golaleh Noorzehi; Parichehr Pasbakhsh; Maryam Borhani-Haghighi; Iraj Ragerdi Kashani; Soheila Madadi; Fatemeh Tahmasebi; Saied Nekoonam; Maryam Azizi
Journal:  J Mol Histol       Date:  2018-08-24       Impact factor: 2.611

Review 7.  Therapeutic Approach to the Management of Pediatric Demyelinating Disease: Multiple Sclerosis and Acute Disseminated Encephalomyelitis.

Authors:  J Nicholas Brenton; Brenda L Banwell
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

8.  One-time intrathecal triamcinolone acetonide application alters the redox potential in cerebrospinal fluid of progressive multiple sclerosis patients: a pilot study.

Authors:  Thomas Müller; Thomas Herrling; Sven Lütge; Lutz Lohse; Gabi Öhm; Katinka Jung
Journal:  Ther Adv Neurol Disord       Date:  2016-03-09       Impact factor: 6.570

Review 9.  Corticosteroids for multiple sclerosis: II. Application for disease-modifying effects.

Authors:  Anjali Shah; Eric Eggenberger; Robert Zivadinov; Olaf Stüve; Elliot M Frohman
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

10.  Genes differentially expressed by methylprednisolone in vivo in CD4 T lymphocytes from multiple sclerosis patients: potential biomarkers.

Authors:  C De Andres; M I García; H Goicoechea; M L Martínez-Ginés; J M García-Domínguez; M L Martín; F Romero-Delgado; A Benguría; M Sanjurjo; L A López-Fernández
Journal:  Pharmacogenomics J       Date:  2016-09-27       Impact factor: 3.550

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.